|
Volumn 8, Issue 5, 2000, Pages 254-256
|
Targeting leukemia cells with Gemtuzumab Ozogamicin
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ANTIBODY CONJUGATE;
ANTINEOPLASTIC ANTIBIOTIC;
CALICHEAMICIN;
CD33 ANTIGEN;
CMA 676;
CYTARABINE;
ETOPOSIDE;
GEMTUZUMAB;
GRANULOCYTE COLONY STIMULATING FACTOR;
MITOXANTRONE;
MONOCLONAL ANTIBODY;
MYLOTARG;
UNCLASSIFIED DRUG;
ACUTE GRANULOCYTIC LEUKEMIA;
ACUTE LEUKEMIA;
ADULT;
AGED;
BONE MARROW TOXICITY;
CLINICAL TRIAL;
DRUG COST;
DRUG EFFICACY;
DRUG INDUCED DISEASE;
DRUG METABOLISM;
DRUG TARGETING;
GASTROINTESTINAL TOXICITY;
HUMAN;
LEUKEMIA CELL;
MAJOR CLINICAL STUDY;
MULTICENTER STUDY;
NEUTROPENIA;
PHASE 3 CLINICAL TRIAL;
REVIEW;
ABDOMINAL PAIN;
ANTIBIOTICS, AMINOGLYCOSIDE;
ANTIBODIES, MONOCLONAL;
ASTHENIA;
DRUG COSTS;
FEVER;
FORECASTING;
HEADACHE;
HUMAN;
IMMUNOTOXINS;
LEUKEMIA, MYELOCYTIC, ACUTE;
NAUSEA;
TREATMENT OUTCOME;
VOMITING;
|
EID: 0033778437
PISSN: 10654704
EISSN: None
Source Type: Journal
DOI: 10.1046/j.1523-5394.2000.85010.x Document Type: Review |
Times cited : (5)
|
References (14)
|